Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNTH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDianthus Therapeutics reports Q1 2026 financial results
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for the quarter ended March 31, 2026. Actual figures not included in the 8-K filing itself.
Item 2.02 verify on EDGAR → -
medium
Full financial details are contained in attached press release (Exhibit 99.1), which is referenced but not summarized in the filing body.
Exhibit 99.1 view on EDGAR →
Summary
Dianthus Therapeutics filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 5, 2026. This is a routine quarterly earnings disclosure required by SEC regulations. The filing itself does not contain the actual financial figures—those details are in the attached press release (Exhibit 99.1). For investors, this is a standard procedural filing.
The material information is in the press release attachment, which typically includes revenue, expenses, cash position, and any operational updates. Retail holders should review the full press release to understand the company's financial health and progress on its therapeutic programs. Watch for any guidance updates or clinical trial milestones mentioned in the release that could affect the stock's near-term trajectory.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Dianthus Therapeutics announced Q1 2026 financial results via press release on May 5, 2026.
Added in current filing · verify on EDGAR →
On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references that a press release was issued with those results.
Event · Item 9.01 — Financial Statements and Exhibits
Dianthus Therapeutics filed an 8-K attaching a press release dated May 5, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1
Press release, dated May 5, 2026
The 8-K references an attached press release dated May 5, 2026, but the filing body does not disclose the content or subject matter of that release. Without access to Exhibit 99.1, the materiality and investor impact cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify